| Name | Title | Contact Details |
|---|---|---|
Daniel Schelp |
Chief Counsel, Regulatory Affairs | Profile |
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Oracle offers a comprehensive and fully integrated stack of cloud applications and platform services.
Pharnext is an advanced clinical stage biopharmaceutical company based in France.
UOLO is Indias top school parent communication app serving over a 1000 schools and 10 lakh Parents! Its the largest and fastest growing messaging platform of India that connects the schools, teachers, kids, parents and others engaged in learning throu...
TradeSun Transforming Trade Finance Find out more Breaking news… TradeSun’s AI platform comes alive to automate global trade finance Today’s global trade finance industry is like a 10-lane highway that narrows to a one-lane bottleneck once it hits the ...